These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 15743913)

  • 21. Depot-medroxyprogesterone acetate: an update.
    Bakry S; Merhi ZO; Scalise TJ; Mahmoud MS; Fadiel A; Naftolin F
    Arch Gynecol Obstet; 2008 Jul; 278(1):1-12. PubMed ID: 18470526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. WHO statement on hormonal contraception and bone health.
    d'Arcangues C
    Contraception; 2006 May; 73(5):443-4. PubMed ID: 16627029
    [No Abstract]   [Full Text] [Related]  

  • 23. Depo-Provera: new concerns--same issues?
    Robinson K
    AWHONN Lifelines; 2005; 9(3):214-7. PubMed ID: 16114743
    [No Abstract]   [Full Text] [Related]  

  • 24. Depot medroxyprogesterone acetate and bone mineral density in adolescents--the Black Box Warning: a Position Paper of the Society for Adolescent Medicine.
    Cromer BA; Scholes D; Berenson A; Cundy T; Clark MK; Kaunitz AM;
    J Adolesc Health; 2006 Aug; 39(2):296-301. PubMed ID: 16857545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Depo Provera--irregular bleeding management.
    Hickey M; Paterson CM
    Br J Fam Plann; 2000 Apr; 26(2):117. PubMed ID: 10896462
    [No Abstract]   [Full Text] [Related]  

  • 26. Longitudinal study of depot medroxyprogesterone acetate (Depo-Provera) effects on bone health in adolescents: study design, population characteristics and baseline bone mineral density.
    Johnson CC; Burkman RT; Gold MA; Brown RT; Harel Z; Bruner A; Stager M; Bachrach LK; Hertweck SP; Nelson AL; Nelson DA; Coupey SM; McLeod A; Bone HG
    Contraception; 2008 Apr; 77(4):239-48. PubMed ID: 18342646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is poor nutrition masking the effects of depomedroxyprogesterone acetate on bones in adolescent users?
    Rianon NJ; Britt RB; Faisel AJ; Shahidullah SM; Leblanc AD
    Singapore Med J; 2010 Nov; 51(11):876-82. PubMed ID: 21140115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In favor of continued use of depot medroxyprogesterone acetate (DMPA, Depo-Provera) in adolescents.
    Cromer B
    J Pediatr Adolesc Gynecol; 2005 Jun; 18(3):183-7. PubMed ID: 15970253
    [No Abstract]   [Full Text] [Related]  

  • 29. Injectable contraception.
    Haider S; Darney PD
    Clin Obstet Gynecol; 2007 Dec; 50(4):898-906. PubMed ID: 17982332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DMPA's effect on bone mineral density: A particular concern for adolescents.
    Schrager SB
    J Fam Pract; 2009 May; 58(5):E1-8. PubMed ID: 19442384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone loss in adolescents using Depo-Provera.
    Kass-Wolff JH
    J Soc Pediatr Nurs; 2001; 6(1):21-31. PubMed ID: 11288500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health.
    Guilbert ER; Brown JP; Kaunitz AM; Wagner MS; Bérubé J; Charbonneau L; Francoeur D; Gilbert A; Gilbert F; Roy G; Senikas V; Jacob R; Morin R
    Contraception; 2009 Mar; 79(3):167-77. PubMed ID: 19185668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Depot medroxyprogesterone acetate contraceptive injections and skeletal health.
    Renner RM; Edelman AB; Kaunitz AM
    Womens Health (Lond); 2010 May; 6(3):339-42. PubMed ID: 20426597
    [No Abstract]   [Full Text] [Related]  

  • 34. Medroxyprogesterone (Depo Provera) and breast cancer.
    McCowan L
    N Z Med J; 1990 May; 103(889):225-6. PubMed ID: 2140436
    [No Abstract]   [Full Text] [Related]  

  • 35. Osteoporosis After Long-Term Depot Medroxyprogesterone: We Need More Data on Fracture Risk.
    Downs RW; Yazbeck CF
    J Womens Health (Larchmt); 2015 Aug; 24(8):619-20. PubMed ID: 26263280
    [No Abstract]   [Full Text] [Related]  

  • 36. Forearm bone mineral density in postmenopausal former users of depot medroxyprogesterone acetate.
    Sanches L; Marchi NM; Castro S; Juliato CT; Villarroel M; Bahamondes L
    Contraception; 2008 Nov; 78(5):365-9. PubMed ID: 18929732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density.
    Kaunitz AM; Darney PD; Ross D; Wolter KD; Speroff L
    Contraception; 2009 Jul; 80(1):7-17. PubMed ID: 19501210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Depo Provera and breast cancer.
    McCowan L; Farquhar C; Roke C; Liddell H; Roberts H; Thakurdas N; Wilson J; Say PJ; McClure F
    N Z Med J; 1991 Jan; 104(904):16-7. PubMed ID: 1826144
    [No Abstract]   [Full Text] [Related]  

  • 39. Depo-Provera--missing the point?
    Fennessy S
    Aust Fam Physician; 1988 Oct; 17(10):839-40. PubMed ID: 2977094
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of the long-term use of depot medroxyprogesterone acetate as hormonal contraceptive on bone mineral density and biochemical markers of bone remodeling.
    Shaarawy M; El-Mallah SY; Seoudi S; Hassan M; Mohsen IA
    Contraception; 2006 Oct; 74(4):297-302. PubMed ID: 16982229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.